Articles in this Issue

  • Does the International Council for Harmonization Offer a Solution via ICH Q12?

    Robert Dream
    The world economies are increasingly threatened by barriers to trade, while the pharmaceutical sector through the International Council for Harmonization (ICH) has been stepping up the effort to dismantle obstacles to global trade in medicines.
  • Transmission Raman Spectroscopy for Pharmaceutical Analysis

    Dr. Johannes Kiefer
    Raman spectroscopy is an established analytical method in the pharmaceutical industry. Micro-spectroscopic setups utilizing the backscattered signal are common in the analysis of solid samples such as tablets.
  • Kolliphor® HS 15 - An Enabler for Parenteral and Oral Formulations

    Dr. Shaukat Ali, Karl Kolter
    Kolliphor® HS 15 is an exceptional solubilizer with attributes suited for parenteral and oral formulation of poorly soluble molecules. As a consequence, it is primarily used in screening of new chemical entities (NCEs) and also used as a vehicle in delivery of molecules encapsulated in micelles or micro-emulsions. Its physicochemical and application relevant characteristics are attributed to a unique structure comprised of 12-hydroxystearic acid (lipophilic moiety) and polyethylene glycol (hydrophilic moiety). As a solubilizer with exceptional safety and toxicity profiles, and regulatory perspectives, it offers unique advantages over many other solubilizers of its class for injectable (IV, infusion, im, sc) formulations, in self-emulsifying drug delivery systems (SEDDS/SMEDDS) and lipid based nanoparticulates.
  • Excluding Burkholderia cepacia complex from Aqueous, Non-Sterile Drug Products

    Tony Cundell, Ph.D.
    This review article will discuss the definition of an objectionable microorganism, the prevalence of members of the Burkholderia cepacia complex (BCC) in U.S. product recall and nosocomial infection outbreaks, why BCC members are serious opportunistic pathogens, the screening and identification methods for members of the complex, and how the risk of microbial contamination of non-sterile drug products can be mitigated.
  • Facility Tour: Eurofins Lancaster Laboratories; Lancaster, PA

    From the time a new, potentially therapeutic substance is discovered to the time it is available to consumers, the clock is ticking. Bio/Pharmaceutical companies need to launch new products as quickly as possible, yet still maintain the highest levels of quality - a quality that is demanded by regulatory agencies and the public.
  • Modeling in Drug Metabolism for Drug Discovery and Development

    Kristen Cardinal, Hao Sun, PhD
    Artificial intelligence comes from sophisticated computer model based “machine learning” and “deep learning.” Microsoft and IBM provide AI infrastructure using modeling tools. Farmers are able to develop intelligent planting, irrigating and harvesting systems to increase yields to feed the expanding population of our planet.
  • An Interview with... Crystal Mersh President and CEO Quality Executive Partners, Inc.

    Having led global quality organizations for many years, I had the opportunity to see first-hand the many challenges of ensuring that employees had the appropriate level of knowledge; and that their knowledge then translated to skills, motivation and commitment to do the right thing when faced with inevitable issues in pharmaceutical manufacturing and analysis.
  • Liquid-Fill Capsules – Benefits for Highly Potent API Formulation and Scale-Up

    Alyn McNaughton
    It is currently estimated that over 25% of all drug products in development have highly potent or highly toxic active pharmaceutical ingredients (API) and require some form of specialized handling. In oncology this figure is likely closer to 70%.1 These types of products represent a growing sector of investment in the pharmaceutical industry, with the market value from existing and new product launches expected to double between 2018 and 2025.2
  • An Interview with... Danielle Clay Director of Global Strategic Marketing and Business Development...

    A series of disciplines in the field of specialized parenterals including personalized medicine, nucleic acid APIs and gene editing are driving demand for advanced drug delivery technologies. These technologies must not only be safe and efficacious, but simple to customize and efficient to manufacture. Other common formulation challenges include the effective penetration of target cells, and ensuring extended release occurs reliably for either systematic or local delivery over days, weeks or months. Technologies such as lipid nanoparticles (LNPs), which can safely encapsulate the API to protect it against degradation while enhancing biodistribution and solubility characteristics, are well positioned to address such challenges.
  • Self-Cleaving Tags Based on Split Inteins: Increased Reliability Enabling Higher Throughput...

    Izabela Gierach, PhD, MBA, MS, David Wood, PhD
    Reliable, consistent, predictable and cost-effective protein purification platforms, with the smallest possible number of steps, are highly desirable for protein research and manufacturing. This is one of the reasons why intervening protein (intein)-based protein purifications have become a focal point among other intein applications.
  • Assessing Aluminum Vaccine Adjuvant Filling, Sedimentation, and Resuspension in Sealed Vials...

    Marc Taraban, PhD, Yihua Bruce Yu, PhD, Christopher B. Fox
    The filling level, sedimentation, and resuspension of aluminum adjuvants (alum) in sealed vials can be quantitatively assessed in situ using the water proton NMR (wNMR) technology. wNMR demonstrates high sensitivity and high throughput capacity (10-40 sec per vial). wNMR makes it possible to quantify alum filling and suspension in every vial in a batch before product release by vaccine makers and before injection by end-users.
  • Pharmaceutical P.I.N. Points Patent Innovation News

    Anvit Vasavada, M.S, Sunny Christian, MS, Amitkumar Lad, PhD, Hemant N. Joshi, PhD, MBA
    The purpose of this column is to highlight and summarize recent key patents in the pharmaceutical arena issued by the US Patent Office in November-December 2018.
  • Application of a Small EF Hand Affinity Tag for Expression, Purification and Biophysical Studies...

    Alexei A. Yeliseev, David J. O’Connell
    Heptahelical G protein-coupled receptors (GPCR) comprise a large family of integral membrane proteins involved in a wide array of cell signaling pathways. For high resolution structural studies of these receptors, multi-milligram quantities of pure and structurally unperturbed proteins are required. Purification of recombinant GPCRs typically involves their solubilization into detergent micelles followed by chromatographic purification. Because of relatively low expression levels of these recombinant receptors, it is challenging to design an efficient strategy for selective and efficient purification with high yield.
  • Facility Design for Continuous Bioprocessing and Smart Manufacturing: Attributes for Success

    Jeff Odum, CPIP
    In testimony given 2013 during a congressional modernization hearing, FDA Director Janet Woodcock clearly outlined the regulatory impetus for the industry’s continued drive to implement continuous manufacturing platforms. She challenged the biomanufacturing organizations to take advantage of advances in process and facility design to help achieve improved manufacturing reliability, increased process robustness, and lowering of manufacturing costs.
  • <<
  • >>